Crinetics Pharmaceuticals Inc
CRNX
Company Profile
Business description
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Contact
6055 Lusk Boulevard
San DiegoCA92121
USAT: +1 858 450-6464
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
437
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
Our analysts believe a long-term margin recovery is underway.
stocks
Two overvalued ASX shares to avoid
Both shares trade at a significant premium to our fair value.
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,888.70 | 17.10 | -0.19% |
| CAC 40 | 8,025.80 | 66.13 | 0.83% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 664.18 | 1.43% |
| FTSE 100 | 9,609.53 | 74.62 | 0.78% |
| HKSE | 26,013.33 | 118.78 | 0.46% |
| NASDAQ | 23,025.59 | 153.59 | 0.67% |
| Nikkei 225 | 49,509.14 | 849.62 | 1.75% |
| NZX 50 Index | 13,562.01 | 81.58 | 0.61% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,596.30 | 19.70 | -0.23% |
| SSE Composite Index | 3,875.48 | 5.45 | 0.14% |